The aim of this retrospective study was to describe the oncologic andfunctionalresults oftreatingoropharyngeal squamous cell carcinoma with transoralrobotic surgery and neck dissection as monotherapy. A review wasperformed, including allpatients who underwenttransoral robotic surgery and neckdissection as the only meansof therapy for oropharyngeal carcinoma from March 2007 to July 2009 at a single tertiary care academic medical center. Wereviewed allcases with ?24-monthfollow-up. Functional outcomes included tracheostomy dependence andoral feeding ability. Oncologic outcomes werestratified by human papillomavirus (HPV)statusand tobacco use andincludedlocal, regional, anddistantdisease control, as well asdisease-specific andrecurrence-freesurvival. Eighteenpatientsmetstudycriteria. Ten patients(55.6%) were able to eat orally in the immediate postoperative period, and 8 (44.4%) required a temporary nasogastric tubefor a mean duration of 13.6 days(range 3 to24 days) before returning to an oraldiet. No patient required placement ofagastrostomy tube, and allpatientsaretracheostomytube-free. Among the HPV-positive nonsmokers (12118, 66.7%), Kaplan-Meier estimated 3-year local, regional, and distant control rates were 90.9%, 100%, and 100%, respectively. Kaplan-Meier estimated disease-specific survivaland recurrence-free survivalwere 100% and90.9%, respectively. No complications occurred.
Introduction
Oropharyngeal squamous cell carcinoma (OPSCCA) is increasing in incidence and is affecting a younger patient population often lacking exposure to traditional head and neck cancer risk factors such as tobacco and alcohol. This changing demographic is commonly attributed to human papillomavirus (HPV), a putative etiologic factor. 1 Most studies demonstrate a survival advantage for HPV-associated OPSCCA relative to those tumors caused by traditional risk factors. ' The optimal treatment strategy for OPSCCA is controversial. Given the excellent disease control and survival of HPV-associated OPSCCA, clinicians must increasingly focus on nononcologic factors, including treatment morbidity, preservation of speech and swallowing function, and treatment cost.
Transoral robotic surgery (TORS) is a relatively new modality for treating OPSCCA. In select cases, we have utilized TORS and neck dissection alone without adjuvant radiotherapy or chemoradiotherapy. This review analyzes patient selection factors and oncologic and functional results achievable when using TORS alone for HPV-associated OPSCCA.
Patients and methods
This studywas approved by the Mayo Clinic Institutional Review Board. All patients who underwent TORS and neck dissection as the only therapy for OPSCCA from March 2007 to July 2009 were included in this review; 18 such patients, with a minimum follow-up of2 years, were included in the analysis. Data were collected from a prospectively maintained institutional database that tracks patient demographics, tumor stage, histopathologic factors, treatment modalities, and functional and oncologic outcomes.
TORS selection criteria were based on both patient and tumor characteristics; the choice of therapy was ultimately determined by physician experience rather than defined metrics. General physical requirements used to estimate whether exposure would be adequate for TORS included oral compliance, neck flexibility, mandibular arch width, presence of mandibular tori, tongue size, and an oropharyngeal tumor estimated to be completely resectable on the basis of preoperative imaging and physical examination.
TORS was offered to select patients with T1 to T3 tumors. During the study period, 203 patients underwent TORS, and 35 patients underwent transoral surgery of another modality for OPSCCA. Patients considered to be poor candidates for transoral surgical approaches were offered open surgical therapy (58 patients). These patients were estimated to have poor exposure, primarily submucosal tumors, mandible or hyoid involvement, extension into deep tongue musculature, extensive involvement of the great vessels, or lateral extension into the soft tissue of the neck.
Patients who refused surgical therapy or who were poor candidates for transoral or open surgery were offerednonoperative therapy (22 patients). Exclusion criteria also included patients with recurrent disease and those who underwent adjuvant radiation therapy, chemotherapy, or chemoradiotherapy as a component of their initial treatment.
This article highlights the results of those select patients who did not undergo adjuvant therapy, either as a result offavorable disease prognosis ( No patients underwent staging direct laryngoscopy prior to TORS. Neck dissections were always performed on the same day as TORS; thus, all patients completed treatment in a single day. Most patients (17/18; 94.4%) underwent unilateral neck dissection. Bilateral neck dissection was performed for one base-of-tongue tumor that approached the midline of the tongue base.
Evidence ofHPV infection was assessed for all cases. HPV DNA was detected via in situ hybridization (ISH) on paraffin -embedded tumor specimens. ISH detection was performed for both low-risk HPV types (6 and 11) and high-risk HPV types (16, 18,31,33,35,39,45,51, 52,56,58, and 66) . Samples with detectable high-risk HPV nucleic acid were regarded as positive.
Protein 16 (p16) assaywas performed on tumor specimens via immunohistochemistry (IHe) on paraffinembedded tumor samples. Detection of p16 marker p 16INK4aby immunohistochemistrywas completed using the CINtec Cytology Kit (mtm laboratories; Heidelberg, Germany). Fresh-frozen tumor samples were frozensectioned and stained according to the manufacturer's protocols with the single modification of postfixation in 4% paraformaldehyde prior to retrieval. Slides were regarded as positive based on strong-diffuse ISH or nrc staining.
Airway patency was determined based on the successful completion of treatment without requiring a tracheostomy or, when tracheostomy was required, by the duration of tracheostomy dependence. Dysphagia was assessed by the incidence and duration of enteral feeding requirements postoperatively and the need for gastrostomy tube placement. Dysphagia was reassessed at the last follow-up and was quantified with the Functional Outcome Swallowing Scale (FOSS). 3 All statistics were performed on commercially available statistical software. OMP 2008; SAS Institute, Inc.; Cary, N.C.) Oncologic outcomes were estimated at 3 years using Kaplan-Meier regression analysis. Patients were followed until the date of death or the last date of contact. was positive in 72.2% (13/18) of cases. All HPV ISHpositive tumors were also p16 IHC-positive. Three tumors (16.7%) were p16 mC-positive and HPV ISHnegative. These 3 patients were lifetime nonsmokers and nondrinkers, aged 52 to 66 years.
Results

Patients. A total of90 patients with previously untreated
Fresh -frozen tumor samples were available for 2 of the 3 HPV ISH-negative patients, which subsequently were evaluated with quantitative real-time polymerase chain reaction (RT-PCR) on fresh-frozen samples. Expression ofHPV oncogenes E6 and E7 measured for HPV 16 and 18. These 3 patients are treated as HPV-positive in the survival analysis.
In this series, 16 of the 18 patients (88.9%) were offered surgeryalone based on favorable patient and tumor characteristics. Two patients (1Ll %) were counseled to undergo adjuvant therapy but declined additional treatment. Patient and tumor characteristics in these 2 patients included a nonsmoker with a T3N2b, HPV+, p16+ tumor with extracapsular nodal extension, and a nonsmoker with a TlN2b, HPV+, p16+ tumor with extracapsular nodal extension. These 2 patients have been followed for 37 and 26 months, respectively, and are alive with no evidence of disease recurrence.
Tumors. Stagingwasperformed in accordance with the American Joint Commission on Cancer (AJCC) Cancer Staging Manual, 6th edition" (table 2) . Preoperatively, all patients selected for TORS had clinical stage Tl/T2 tumors; 1 patient was restaged as T3 postoperatively. Treatment. Primary tumor resection was performed using the da Vinci Surgical System (Intuitive Surgical, Inc.; Sunnyvale, Calif.). Our technique for using TORS in the treatment of OPSCCA has previously been described.' The procedure was not abandoned in any case because of poor exposure or inability to complete the resection. Margins were successfully cleared on frozensection pathology intraoperatively.
In 11 patients (6Ll %), surgical margins were clear on the initial resection; 4 patients (22.2%) required a second margin excision at the time of the initial operation; 3 patients (16.7%) required two or more margin excisions at the time of the initial operation. The mean duration of hospitalization was 3.1 days (range: 1 to 4 days), when counting the date of surgery as day zero.
Complications. No perioperative or postoperative complications occurred in this patient series.
Functional outcomes. Airway. Temporary tracheostomy was performed in 3 patients (16.7%) for airway protection during the postoperative period. Two of these patients underwent tracheostomy after resection ofT2 
Kaplan-Meier 3-year disease control and survival analysis: Tobacco and HPV.
Three-year estimated local controlfor HPV-positive nonsmokers (n = 12)was 90.9%, regional control was 100%,and distant control was 100%. Disease-specific survival was 100%,and recurrence-free survival was 90.9%. Three of the 5 patients who were smokers developed recurrent disease. A statistically significant increased recurrence-free survival was thus noted for all nonsmokers (n = 13) versus smokers (n = 5): 92.3% versus 30.0% (p = 0.05). Recurrence-free survival for HPV-positive (n =13)versus HPV-negative (n = 5) patients: 92.3% versus 0.0% (p= 0.04) (table 6).
Histopathologic finding
No. (%) 
Oncologic outcomes. Two-year minimum follow-up.
Eighteen patients were followed for a minimum of 2 years after surgery (range: 24 to 51 months; mean: 32.1 months). No patients were lost to follow-up. Seventeen patients (94.4%) were alive and disease-free at the time of this review. One patient (5.6%) died of disease; no patients died from any other cause.
Recurrent disease. Four patients (22.2%) developed recurrent disease. Three of these patients (75%) were Table 3 . Tumor histopathology in the 18 patients 
ANED, 26 rno
Key: HPV = human papillomavirus; Tx = treatment; RR = regional recurrence; CRT = chemoradiation therapy; ANED = alive with no evidence ofdisease; LRR = locoregional recurrence; DOD = dead ofdisease; LR = local recurrence; RT = radiation therapy.
The term organ preservation therapy has been used to describe treatment modalities that aim to preserve function ofthe target organ. For oropharyngeal tumors, organ preservation therapy generally refers to treatment modalities that allow patients the ability to swallow, to speak orally, and to breathe without the use of a tracheostomy tube.
Transoral surgery ofthe oropharynx is one method of "preserving the organ:' Transoral surgery for OPSCCA has evolved from transoral surgery with handheld cautery? to transorallaser microsurgery," and recently to transoral robotic surgery.-" Although transoral laser microsurgery and transoral robotic surgery have differences in the retractors used to expose the tumor, the size and cost ofthe instrumentation, and the patient selection criteria, the oncologic and functional results oftransoral robotic surgery reported in this study substantiate what has been found in other transoral surgical series: Swallowing function and airway patency can be preserved through a minimally invasive transoral surgical approach. In the end, transoral surgery for oropharyngeal cancer removal is more dependent on the experience and judgment of the operator than the tool used.
All patients in our series were able to maintain their nutritional needs orally within 4 weeks ofsurgery, and at last follow-up, all patients had normal or nearly normal swallowing function. Preservation of swallowing function in patients treated with transoral surgery alone is a major benefit of this technique.
Garden et al reported results of intensity-modulated radiation therapy with or without concurrent chemotherapy for small (<4 ern) primaryoropharyngeal tumors (n =: 5l)Y Gastrostomy tube placement was required in 21 patients_(40%) during therapy, 4 of whom required gastrostomy tubes for longer than 6 months. Garden's study included a greater percentage of advanced-stage tumors than ours, however, making comparisons impos-Volume 92, Number 2 sible. Nonetheless, the low incidence and short duration of enteral feeding required in our series suggests that the swallowing results achieved are acceptable when compared to those of modern nonoperative treatment for similar T-stage tumors.
Oncologic outcomes for patients with oropharyngeal cancer have improved in the past several decades. Modern series no longer report the 50 to 60% disease-specific survival that was common in the studies reviewed by Parsons et al. 6 The sources ofthis change are more likely the changing etiologyand pathophysiologyofthe disease rather than advances in treatment efficacy.
A causative factor in many of the OPSCCAs today is HPV. HPV-mediated OPSCCA has been shown in many studies to have a favorable prognosis.P:" HPV DNA was detected by ISH in 55.6% ofthe tumors in our series, and p 16 positivity by IHC was detected in 72.2%. This rate of HPV positivity is similar to that detected in other modern series of OPSCCA.14Understanding the exact role of HPV activity as an etiologic factor in oropharyngeal cancer is still under investigation, but it now appears clear that HPV-associated tumors behave favorably when compared with OPSCCAs related to tobacco and alcohol.
Few studies have looked at transoral surgery and neck dissection alone to control oropharyngeal carcinoma, and we are not aware of any studies evaluating TORS alone for oropharyngeal cancer treatment. Grant et al reviewed 69 patients who underwent transoral laser microsurgery and neck dissection alone for OPSCCA and achieved a 5-year survival rate of 86% and a local control rate of 94%.rs Grant's results are comparable to the results presented here. Interestingly, in our series, while local and regional control in the HPV-positive nonsmokers was 90.9% and 100%, respectively, the results were significantly worse among smokers and those with HPV-negative tumors.
www.entjournal.com • 81 While the numbers in this study were small, these differences achieved significance. We do not advocate for surgery alone for most cases involving smokers with HPV-negative tumors. Currently, many centers recommend primarychemoradiation for treatment of oropharyngeal cancers. Modern series have demonstrated the excellent oncologic results achievable with nonoperative therapy for OPSCCA. Mendenhall et al reported a 92%local control rate for stage I to II OPSCCA and 85% 5-year causespecific survival for all disease stages when intensitymodulated radiotherapy was used." With this modern nonoperative benchmark in mind, the results of TORS alone were comparable in terms of oncologic outcomes for HPV-associated OPSCCA among non-smokers.
Treatment with surgery alone offers both advantages and disadvantages when compared to nonoperative treatment. Surgery carries the up-front risks of anesthesia complications, bleeding, postoperative pain, fistula formation, and iatrogenic injury to critical neurovascular structures. Despite these disadvantages, patients treated with surgery alone avoid the risks of radiation and/or chemoradiation, such asxerostomia, osteoradionecrosis, mucositis, renal failure, sepsis, pharyngeal and esophagealscarring/stenosis, and muscle fibrosis. Furthermore, surgical treatment can be completed in a single day with a short hospital stay and a rapid return to function.
Fortunately, the morbidity of treatment in our series was very low. In our institution, surgical treatment is also significantly less expensive than non operative therapy."
Ultimately, there is no single best treatment option for patients with OPSCCA. The modern-day head and neck oncologist must take into consideration the tumor 82 " www.entjournal.com etiology, biology, and prognostic factors. Additionally, the patient's health, functional priorities, lifestyle, and work requirements, the duration and cost of treatment, the expected morbidity of treatment, and the oncologic efficacy of each intervention must be carefully considered and individualized. Clinicians require a working knowledge of all treatment options and must ultimately set bias aside and provide recommendations with the best interest of the patient in mind. We propose that TORS alone is an excellent option for appropriately selected patients.
The major limitations of this study are the small number of patients and the inherent selection bias of the study group. An additional limitation is the follow-up duration, which may fail to capture late disease recurrences and distant metastases.
Well-designed comparison studies investigating the oncologic and functional results of the different treatments for HPV-associated OPSCCA are needed. Studies such as ours demonstrate the need for surgical management to be included in comparative trials for OPSCCA.
In conclusion, we believe transoral surgery with complete primary tumor removal and neck dissection is an effective therapy for select HPV-positive OPSC-CAs. The role of transoral surgery for oropharyngeal malignancies related to tobacco requires further study. Documenting p16and HPV status on diagnostic biopsies should be considered important in treatment planning, given the difference in oncologic outcomes. The ability to accurately stage the tumor and to treat the primary tumor and lymph nodes in a single treatment episode is unique to a primary surgical approach.
Transoral surgery and neck dissection in this select group of patients results in excellent oropharyngeal function. In nonsmoking patients with HPV-positive tumors, TORSoffersashort treatment duration, minimal treatment morbidity, and excellent oncologic control. This approach facilitates individualized care of the patient with OPSCCA.
